Palisade Bio received No Objection Letter from Health Canada for Phase 1 study

Palisade Bio announced that it has received a No Objection Letter from Health Canada for its Phase 1 human clinical study for PALI-2108 for the treatment of UC. The study is a Phase 1 Single Ascending Dose /Multiple Ascending Dose and food effects and includes multiple dose treatment of UC patients; Global UC market is expected to grow to nearly $10 Billion by 2028. “We are thrilled to receive a No Objection Letter from Health Canada in response to our Clinical Trial Application. This achievement marks the most important milestone to date for our PALI-2108 development program. We continue to believe in the potential of PALI-2108 to be the first approved PDE4 inhibitor for UC and more importantly, provide a much-needed effective and safe solution for UC patients still experiencing significant medical need. Our team remains focused on continuing preparations for the initiation of our Phase 1 clinical trial which is on track to commence before year end,” commented J.D. Finley, Chief Executive Officer.